IFC Holdings Incorporated FL grew its stake in Pfizer, Inc. (NYSE:PFE) by 1.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,447 shares of the biopharmaceutical company’s stock after purchasing an additional 1,023 shares during the quarter. IFC Holdings Incorporated FL’s holdings in Pfizer were worth $2,432,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Keystone Financial Planning Inc. lifted its holdings in shares of Pfizer by 3.2% in the second quarter. Keystone Financial Planning Inc. now owns 187,549 shares of the biopharmaceutical company’s stock valued at $6,300,000 after purchasing an additional 5,741 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Pfizer by 6.5% in the second quarter. Teacher Retirement System of Texas now owns 3,994,833 shares of the biopharmaceutical company’s stock valued at $134,186,000 after purchasing an additional 244,575 shares in the last quarter. Patton Albertson Miller Group LLC lifted its holdings in shares of Pfizer by 2.6% in the second quarter. Patton Albertson Miller Group LLC now owns 6,705 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 168 shares in the last quarter. Granite Investment Advisors LLC lifted its holdings in shares of Pfizer by 3.3% in the second quarter. Granite Investment Advisors LLC now owns 8,635 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 277 shares in the last quarter. Finally, Wedge Capital Management L L P NC bought a new position in shares of Pfizer in the second quarter valued at approximately $214,000. Institutional investors own 69.36% of the company’s stock.
A number of research analysts have recently weighed in on the company. Berenberg Bank restated a “hold” rating and issued a $36.00 target price (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Goldman Sachs Group, Inc. (The) set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. BMO Capital Markets reiterated a “buy” rating and set a $39.00 price target on shares of Pfizer in a report on Friday. Finally, J P Morgan Chase & Co set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $38.48.
In other news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the transaction, the insider now owns 132,124 shares of the company’s stock, valued at $4,492,216. The disclosure for this sale can be found here. Over the last quarter, insiders sold 374,621 shares of company stock valued at $12,796,098. 0.06% of the stock is owned by company insiders.
Pfizer, Inc. (NYSE PFE) opened at $35.18 on Monday. The firm has a market capitalization of $209,697.67, a price-to-earnings ratio of 14.07, a PEG ratio of 2.49 and a beta of 1.01. Pfizer, Inc. has a 52-week low of $30.51 and a 52-week high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.61 earnings per share. analysts anticipate that Pfizer, Inc. will post 2.59 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.64%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.